GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.
Guillem Pascual-PastoBrendan McIntyreRawan ShraimSamantha N BuongervinoAmy K ErbeDoncho V ZhelevShakhnozakhon SadirovaAnna Maria GiudiceDaniel MartinezLaura Garcia-GeriqueDimiter S DimitrovPaul M SondelKristopher R BossePublished in: Journal for immunotherapy of cancer (2022)
We elucidated the immunoregulatory properties of a GPC2-targeted ADC and showed robust efficacy of combination immunotherapies in diverse neuroblastoma preclinical models.